

DORSET MEDICINES ADVISORY GROUP

Recommendation Summary



**Dorset
Clinical Commissioning Group**

The Dorset Medicines Advisory Group (DMAG) represents the four provider Trusts and GPs within the Clinical Commissioning Group (CCG). It provides recommendations to the CCG on the prescribing and commissioning of medicines.

Summary of recommendations considered at a meeting of the group on September 2019. Formulary entries and associated documents can be accessed at www.dorsetformulary.nhs.uk.

PRODUCT	DECISION		COMMENTS
	Previous position	Recommended position	
1. Products re-categorised			
2. New requests			
Risankizumab	Red		In accordance with NICE TA 596 and Commissioning Statement The Psoriasis pathway was noted with the inclusion of risankizumab.
Xonvea® (doxylamine pyridoxine)	Non Formulary		Antiemetic licensed for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management
Sodium Zirconium Cyclosilicate	Red		Added in accordance with the NICE TA 599 and commissioning statement.
Fluocinolone Implant	Red		Indication added in accordance with the NICE TA 590 and commissioning statement.
Dapagliflozin	Red		Indication added in accordance with NICE TA 597 Dapagliflozin, with insulin for treating type 1 diabetes and commissioning statement

PRODUCT	DECISION	COMMENTS
3. Products considered by NICE		
NICE TA 596 - Risankizumab for treating moderate to severe plaque psoriasis NICE MTG42 - UrgoStart for treating diabetic foot ulcers and leg ulcers NICE TA 599 - Sodium Zirconium Cyclosilicate NICE TA 590 – Fluocinolone acetonide intravitreal implant NICE TA 597 – Dapagliflozin, with insulin for treating type 1 diabetes		
4. Miscellaneous recommendations by DMAG		
Melatonin product licensed for jet lag in adults	Non Formulary and included in the CCG’s overseas travel medicine policy	only to be issued on a private prescription. The “Dorset CCG Prescribing for Overseas Travel” policy has been updated to reflect this
A statement on hosiery appliances to be added to formulary		“ Hosiery appliances: there is currently no formulary for hosiery appliances. Please ensure that patients are using the most cost effective and clinically appropriate appliance following details in the Drug Tariff. Please see the link to the NHSBSA here for the latest version of the Drug Tariff.”
Botulinum Toxin Type A. Criteria based Access Protocol: Amendment to the CBAP		Amendment to the CBAP following NICE NG46
UrgoStart® plus pad and border		All sizes to be added to the Formulary in line with NICE MTG42
Clearfilm® to be added to formulary		In place of C-view®
The antibiotic formulary entries updated to highlight different		In line with Bronchiectasis (acute exacerbation) NICE NG117 and COPD (acute exacerbation) NICE NG114 on antimicrobial prescribing.

PRODUCT	DECISION	COMMENTS
treatment courses according to different indications.		
5. Further Assessment / Evidence Required		
6. New documents approved		
<p>THE DIABETIC FOOT ULCER PATHWAY</p> <p>COMMISSIONING STATEMENT ON RISANKIZUMAB FOR TREATING MODERATE TO SEVERE PAQUE PSOIASIS</p> <p>COMMISSIONING STATEMENT ON THE USE OF SODIUM ZIRCONIUM CYCLOSILICATE FOR TREATING HYPERKALAEMIA</p> <p>COMMISSIONING STATEMENT ON THE USE OF FLUOCINOLONE ACETONIDE IN RECURRENT NON-INFECTIOUS UVEITIS</p> <p>COMMISSIONING STATEMENT ON THE USE OF DAPAGLIFLOZIN WITH INSULIN FOR TREATING TYPE 1 DIABETES</p>		
7. Documents Reviewed		
<p>Commissioning statement for Biosimilars reviewed and updated</p> <p>Commissioning statement for positive expiratory pressure devices</p> <p>The Psoriasis Pathway, updated to include risankizumab</p>		

Classification of products:

'RED' drugs for hospital use only

'AMBER with shared care' drugs suitable for use with shared care arrangements

'AMBER' drugs suitable for use without shared care arrangements

'GREEN' drugs suitable for prescribing in primary and secondary care

'Not Recommended' – drugs not recommended for use in Dorset